
Gossamer Bio GOSS
$ 0.22
8.14%
Quarterly report 2026-Q1
added 05-15-2026
Gossamer Bio Total Current Liabilities 2011-2026 | GOSS
Annual Total Current Liabilities Gossamer Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.4 M | 45 M | 51.6 M | 49.2 M | 39.9 M | 38.6 M | 36.9 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.4 M | 36.9 M | 46.4 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
6.4 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
301 M | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
38.5 M | $ 34.45 | 4.74 % | $ 927 M | ||
|
Forte Biosciences
FBRX
|
20.8 M | $ 20.31 | 1.2 % | $ 263 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 6.82 | 1.94 % | $ 187 M | ||
|
Generation Bio Co.
GBIO
|
35.1 M | - | - | $ 344 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.62 | -0.61 % | $ 431 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.33 M | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
22.6 M | $ 2.71 | -0.92 % | $ 253 M | ||
|
Anika Therapeutics
ANIK
|
21.9 M | $ 15.14 | 2.16 % | $ 217 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Incyte Corporation
INCY
|
1.52 B | $ 97.08 | 1.55 % | $ 19 B | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.39 | 4.17 % | $ 5.58 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
140 M | $ 1.51 | 2.03 % | $ 177 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 20.47 | 4.97 % | $ 2.6 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K |